QIAGEN has entered into a binding agreement with Ipsogen co-founders Vincent Fert and Stephane Debono, board member Kevin Rakin, Amundi Asset Management and Matignon Investissement and other shareholders to purchase 61% of company’s share capital.
Under the agreement QIAGEN will have access to Ipsogen’s assays which cover 15 biomarkers used for the diagnosis, prognosis and monitoring of patients with various blood cancers.
Ipsogen’s CE-IVD marked assays are developed for use on QIAGEN’s Rotor-Gene Q real-time PCR system.
This will enable the smooth and rapid transfer of these unique products onto QIAGEN’s QIAsymphony RGQ, a novel integrated sample-to-result laboratory automation platform that includes the Rotor-Gene Q system.
QIAGEN plans to purchase remaining shares.
Ipsogen provides molecular profiling and personalized healthcare diagnostics which are applied in the field of hematology.
